Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: A randomized trial

Journal of the American Medical Association

Volumn 288, Issue 2, 2002, Pages 189-198

  Dorenbaum, Alejandro ^a   Cunningham, Coleen K ^b   Gelber, Richard D ^c   Culnane, Mary ^d   Mofenson, Lynne ^e   Britto, Paula ^c   Rekacewicz, Claire ^f,g   Newell, Marie Louise ^h   Dclfraissy, Jean Francois ^f,i   Cunningham Schrader, Bethann ^j   Mirochnick, Mark ^k   Sullivan, John L ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f Agence Nationale de Recherches sur le SIDA   (France)

^g INSERM   (France)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ BICÊTRE HOSPITAL   (France)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NEVIRAPINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CESAREAN SECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MATERNAL DISEASE; MULTICENTER STUDY; NEWBORN DISEASE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRENATAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STILLBIRTH; VAGINAL DELIVERY; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 0037055088     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.2.189     Document Type: Article

References (26)

1. Prevention of perinatal HIV transmission during pregnancy
2. Estimated timing of mother-to-child human immunodeficiency virus type 1 transmission by use of a Markov model
3. Reduction of maternal-infant transmission of the human immunodeficiency virus type 1 with zidovudine treatment
4. Efficacy of zidovudine and hyperimmune HIV immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease
5. After AIDS Clinical Trials Group 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants
6. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France
7. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates
8. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-infected Ugandan women and their neonates (HIVNET 006)
9. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV in Kampala, Uganda
10. Maternal factors associated with perinatal HIV transmission
11. HIV-Infected pregnant women and vertical transmission in Europe since 1986
12. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group
13. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories
14. Proposed definitions for in utero versus intrapartum transmission of HIV
15. Multicenter review of protease inhibitors in 89 pregnancies
16. Trends in antiretroviral therapy and mother-infant transmission of HIV
17. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1
18. Lamivudine-zidovudine combination for the prevention of maternal-infant transmission of HIV
19. The SAINT trial: Nevirapine versus zidovudine+lamivudine (3TC) in prevention of peripartum HIV transmission
20. Evaluation of safety of two simple regimens for prevention of mother to child transmission (MCTC) of HIV infection
21. Impact of human immunodeficiency virus type 1 (HIV) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV vertical transmission (HIV network for prevention trials 012 study)
22. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
23. Genotypic resistance analysis in women participating in PACTG 316 with HIV RNA >400 copies/mL
24. Genotypic resistance analysis in French women participating in PACTG 316/ANRS 083